Navigation Links
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Date:11/8/2007

Fong will lead sales and marketing of CTI products

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that Jim Fong has been appointed the company's Vice President, Commercial Operations. Fong joins CTI with more than 20 years of sales and marketing experience. Most recently, Fong was National Sales Director at CV Therapeutics (CVT) in Palo Alto, California, where he led the launch of Ranexa(R) for chronic angina. CTI recently agreed to acquire the drug ZEVALIN(R) from Biogen Idec for development, marketing, and sale in the United States. Closing of the acquisition, which remains subject to closing conditions including obtaining certain third party consents, is expected in mid-November.

"Jim did a great job at the launch of Ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent Camptosar(R), Jim has the ideal credentials to positively impact the ZEVALIN relaunch while optimizing the positioning of our future oncology products like pixantrone," noted James A. Bianco, M.D., President and CEO of CTI.

Fong, who will report directly to Dr. Bianco, will be in charge of directing the sales and promotion of CTI products at the national and international levels. This will include product positioning, promotional programs, reimbursement strategies, and development and training of a national sales force.

"I am very pleased to join the CTI team and help re-establish a strong sales and marketing presence for the company," said Fong. "ZEVALIN is a great product and CTI is on an upward growth path with multiple opportunities for product launches in the coming years."

At CVT, Fong managed a sales team of more than 200 people, including business managers, marketing and sales operations, and the sales training department. Prior to CVT, Fong directed several sales teams and also had previous oncology experience at Pharmacia in launching Camptosar. Fong holds a BS from UCLA in Psychology.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of ZEVALIN and our other potential products include risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN in particular including, without limitation, the potential failure to obtain regulatory approval for label expansion of ZEVALIN, other determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling ZEVALIN. In addition, there is a risk that we may not be able to complete the acquisition of ZEVALIN due to closing conditions, including the need to obtain certain third party consents, or that we may not recognize the full expected value of ZEVALIN in future years. In addition, you should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. WorldHeart Appoints David Pellone Chief Financial Officer
8. Novo Nordisk Appoints New Leader of North American Business
9. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
10. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
11. Resonant Medical Appoints New Vice President of Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow up ... talent of your dental team at presenting treatment, there will always be some patients ... of time and money on best practices when it comes to presenting treatment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to announce ... in USA Today, which will educate readers on how to take care of all ... large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, shares ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business ... focus on current legislative activity and the latest regulatory concerns impacting RBMA members. ... Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons ...
(Date:5/26/2017)... , ... May 26, 2017 , ... A new analysis ... with the healthiest seniors are located in the Midwest. With the average cost of ... more people are concerned with both the quality and affordability of where they live. ...
(Date:5/26/2017)... BOSTON, MA (PRWEB) , ... May 26, 2017 , ... ... Care Act (AHCA), which narrowly passed the U.S. House on May 4, would result ... would be expected under continued implementation of the 2010 Patient Protection and Affordable Care ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... -- May is Stroke Awareness Month and Omron Healthcare is ... to prevent a stroke: monitor and manage your blood ... Prevention, undetected and uncontrolled hypertension is a leading risk ... in personal heart health technology, recently evolved its mission ... stroke and is advancing a national public education effort ...
Breaking Medicine Technology: